Pegzilarginase - Aeglea BioTherapeutics

Drug Profile

Pegzilarginase - Aeglea BioTherapeutics

Alternative Names: AEB-1102; AERase; Co-ArgI-PEG - Aeglea Biotherapeutics; Co-ArgI-PEG modified human arginase I - Aeglea Biotherapeutics; Optimised human arginase I - Aeglea Biotherapeutics; PEG-arginase - Aeglea Biotherapeutics; Pegarginase - Aeglea Biotherapeutics

Latest Information Update: 21 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aeglea Biotherapeutics
  • Class Antineoplastics; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperargininemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hyperargininemia
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 16 Oct 2017 Aeglea BioTherapeutics and Merck agree to co-develop Pegzilarginase (Combination therapy) in USA for Small cell lung cancer
  • 16 Oct 2017 Aeglea Biotherapeutics plans a phase I/II trial for Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) in the first quarter of 2018
  • 23 May 2017 Aeglea Biotherapeutics receives an information request from the FDA for AEB 1102 in Arginase I deficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top